OnCo

Rhabdomyosarcoma: lines of therapy

Cancer page →

4 standard-of-care settings across 3 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comersRisk group
Early / localised·2
Advanced, first line·1
Second line1·

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
Risk groupLow risk (embryonal, favourable site, complete resection)VA ± reduced cyclophosphamide for 22-24 weeks; radiotherapy for microscopic residual disease.39
Risk groupIntermediate riskVAC (or VAC/VI) 42 weeks with radiotherapy at week 13 (COG); IVA with maintenance vinorelbine-cyclophosphamide 6 months (EpSSG); temsirolimus-VAC/VI per ARST1431 where adopted.91

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
Risk groupHigh risk (metastatic)Intensive multi-agent chemotherapy (VAC/IE, vincristine-irinotecan windows) with radiotherapy to primary and metastases; maintenance; FaR-RMS trial questions.91

Second line

SubgroupSettingApproachProducts and trialsEvidence
All comersRelapsedVinorelbine-cyclophosphamide, irinotecan-temozolomide, surgery/RT; trials (mTOR, FGFR4, CDK4/6, IGF-1R, B7-H3 CAR-T).85

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.